NCT04918888

COVID-19 Vaccination in Oncologic Patients

SARS-CoV-2 Vaccination in Oncologic Patients: A Prospective, Explorative Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,150 (actual)
• Sponsor: Krankenhaus Barmherzige Schwestern Linz · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

Evaluating the vaccination willingness in oncologic patients over six months as well as estimating the effects of radiotherapy/systemic anticancer treatment on the efficacy and toxicity of currently approved SARS-CoV-2 vaccines

Detailed description

All patients that present themselves newly at the outpatient-clinic of the Department of Radiooncology at the Ordensklinikum Linz GmbH, Barmherzige Schwestern during a period of six months are eligible for participation. After being informed about the study, the participants answer a short structured interview regarding vaccination status and vaccination willingness. Patients who already received one or two doses of SARS-CoV-2 vaccine are eligible for the study's subpopulation 1, with the main focus of quantifying SARS-CoV-2 S binding antibody titres after at least 35 days from initial vaccination. Patients who are to receive at least one dose of vaccine during or up to six weeks after radiotherapy are eligible for subpopulation 2, comprising serial measurements of SARS-CoV-2 S binding antibody titres before and after vaccination.

Conditions

• Covid19
• Oncologic Disorders

Timeline

• Start date: 2021-04-19
• Primary completion: 2021-09-30
• Completion: 2021-09-30
• First posted: 2021-06-09
• Last updated: 2021-11-23

Locations

2 sites across 1 country: Austria